代谢综合征与分化型甲状腺癌的发生及严重程度的相关性

Corralation between metabolic symdrome and the occurrence and severity of differentiated thyroid carcinoma

目的:分析代谢综合征及其组分与分化型甲状腺癌的发生及严重程度的相关性。方法:收集自2020年06月至2022年06月在我院因甲状腺结节行手术治疗,术后病理确诊为分化型甲状腺癌的285例患者以及病理确诊为良性甲状腺结节的138例患者的临床资料,根据病理结果,分为良性组138例和恶性组285例;根据是否合并代谢综合征,将恶性组患者分为甲癌组156例和甲癌合并代谢综合征组129例。结果:恶性组患者BMI平均数及代谢综合征占比明显高于良性组,恶性组年龄平均数低于良性组,且存在显著性差异(P<0.05);甲癌合并代谢综合征组患者较甲癌组体质量指数、血压、空腹血糖、甘油三酯、肿瘤直径≥1、肿瘤位于双侧甲状腺、肿瘤多灶均高(P<0.05),高密度脂蛋白胆固醇水平低(P<0.05)。结论:合并代谢综合征的甲状腺结节患者恶性可能性更高,且在肿瘤直径、肿瘤位置、癌灶数量方面较未合并代谢综合征者表现出更严重的倾向,提示代谢综合征可能是影响甲状腺恶性肿瘤严重程度的危险因素。

Objective:To investigate the correlation between metabolic syndrome and its components and the occurrence and severity of differentiated thyroid carcinoma.Methods:The clinical data of 423 patients underwent surgical treatment for thyroid nodules during June 2020 and June 2022 were retrospectively collected.According to the pathological results,they were divided into 138 cases of benign nodule and 285 cases of malignant nodule.According to whether they had metabolic syndrome,285 cases of malignant nodule were divided into 156 cases of differentiated thyroid carcinoma and 129 cases of differentiated thyroid carcinoma combined with metabolic syndrome.Results:The mean BMI and the proportion of metabolic syndrome in the malignant group were significantly higher than those in the benign group,and the mean age in the malignant group was lower than that in the benign group(P<0.05).The mean of body mass index,blood pressure,fasting blood glucose,triglyceride,and number of tumor size≥1,tumor in bilateral thyroid,multifocal tumor in patients with differentiated thyroid cancer combined with metabolic syndrome were higher than those in patients without metabolic syndrome(P<0.05),and the level of high-density lipoprotein cholesterol was lower(P<0.05).Conclusion:The thyroid nodules patients with metabolic syndrome were more likely to be malignant than those without metabolic syndrome,and showed more serious tendency in tumor size,tumor location,and number of cancer foci,suggesting that metabolic syndrome may be a risk factor affecting the severity of thyroid malignant tumors.